HANXBIO-B Repurchases 44,000 H Shares for HK$1.14 Million, Treasury Stock Rises to 1.59 Million Shares

Bulletin Express06-26

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) disclosed a share repurchase on 26 June 2026 under its authorised buy-back mandate approved on 24 June 2026. The company bought back 44,000 H shares on the Hong Kong Stock Exchange at prices between HK$24.96 and HK$28.00 per share, representing a volume-weighted average cost of HK$25.797. The total consideration was approximately HK$1.14 million.

Following the transaction, the number of issued shares (excluding treasury shares) declined to 134.63 million, down 0.033 percent from 134.67 million previously. Treasury shares increased to 1.59 million, while the company’s total issued share count remained unchanged at 136.22 million.

Under the current repurchase mandate, HANXBIO-B is authorised to repurchase up to 13.47 million shares. Cumulative buy-backs since the mandate’s approval have reached 66,800 shares, or 0.0496 percent of the company’s issued share capital as at the mandate date.

In accordance with Hong Kong listing rules, HANXBIO-B is subject to a moratorium on issuing new shares or selling treasury shares until 26 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135861641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135861641","market":"us","top_or_hot":-1,"title":"HANXBIO-B Repurchases 44,000 H Shares for HK$1.14 Million, Treasury Stock Rises to 1.59 Million Shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) disclosed a share repurchase on 26 June 2026 under its authorised buy-back mandate approved on 24 June 2026. The company bought back 44,000 H shares on the Hong Kong Stock Exchange at prices between HK$24.96 and HK$28.00 per share, representing a volume-weighted average cost of HK$25.797. The total consideration was approximately HK$1.14 million.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) declined to 134.63 million, down 0.033 percent from 134.67 million previously. Treasury shares increased to 1.59 million, while the company’s total issued share count remained unchanged at 136.22 million.</p>\n<p>Under the current repurchase mandate, HANXBIO-B is authorised to repurchase up to 13.47 million shares. Cumulative buy-backs since the mandate’s approval have reached 66,800 shares, or 0.0496 percent of the company’s issued share capital as at the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, HANXBIO-B is subject to a moratorium on issuing new shares or selling treasury shares until 26 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Repurchases 44,000 H Shares for HK$1.14 Million, Treasury Stock Rises to 1.59 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Repurchases 44,000 H Shares for HK$1.14 Million, Treasury Stock Rises to 1.59 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-26 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) disclosed a share repurchase on 26 June 2026 under its authorised buy-back mandate approved on 24 June 2026. The company bought back 44,000 H shares on the Hong Kong Stock Exchange at prices between HK$24.96 and HK$28.00 per share, representing a volume-weighted average cost of HK$25.797. The total consideration was approximately HK$1.14 million.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) declined to 134.63 million, down 0.033 percent from 134.67 million previously. Treasury shares increased to 1.59 million, while the company’s total issued share count remained unchanged at 136.22 million.</p>\n<p>Under the current repurchase mandate, HANXBIO-B is authorised to repurchase up to 13.47 million shares. Cumulative buy-backs since the mandate’s approval have reached 66,800 shares, or 0.0496 percent of the company’s issued share capital as at the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, HANXBIO-B is subject to a moratorium on issuing new shares or selling treasury shares until 26 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1135861641","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135861641","pubTimestamp":1782473152,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) disclosed a share repurchase on 26 June 2026 under its authorised buy-back mandate approved on 24 June 2026. The company bought back 44,000 H...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉思生物-B 114万港元回购4.4万股H股库存股升至159万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) disclosed a share repurchase on 26 June 2026 under its authorised buy-back mandate approved on 24 June 2026. The company bought back 44,000 H shares on the Hong Kong Stock Exchange at prices between HK$24.96 and HK$28.00 per share, representing a volume-weighted average cost of HK$25.797. The total consideration was approximately HK$1.14 million.\nFollowing the transaction, the number of issued shares (excluding treasury shares) declined to 134.63 million, down 0.033 percent from 134.67 million previously. Treasury shares increased to 1.59 million, while the company’s total issued share count remained unchanged at 136.22 million.\nUnder the current repurchase mandate, HANXBIO-B is authorised to repurchase up to 13.47 million shares. Cumulative buy-backs since the mandate’s approval have reached 66,800 shares, or 0.0496 percent of the company’s issued share capital as at the mandate date.\nIn accordance with Hong Kong listing rules, HANXBIO-B is subject to a moratorium on issuing new shares or selling treasury shares until 26 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135861641","isCrawlerRequest":true}